Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : MDA - Market Direction Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Haim R. Branisteanu who wrote (44079)	3/25/2000 8:08:00 AM
From: Crimson Ghost	Respond to of 99985

Charles Schwab now has a bigger market cap than General Motors. Perhaps the noun "mania" is not strong enough to describe the madness in the markets today.

To: Haim R. Branisteanu who wrote (44079)	3/25/2000 12:36:00 PM
From: Greg Jung	Read Replies (1) \| Respond to of 99985

In biotech at least you have something to work with, some sort of cash flow analysis to attempt. Try that with Yahoo to justify a reasonable fraction of its share price. In any case, your 5-10 year for a drug is based on the organic chemistry lab method of pre-clinical development. When molecular biology is brought to bear, much better efficiencies at discovery are possible. The science has rapidly advanced and that advancement is accelerating as it gets rewarded. Maybe we still have a 5-10 year horizon for any single remedy, but how many more can we start the process in, using modern techniques? BTW business models of CRA, INCY, GLGC - as "informatics" I also see as premature since they don't seem to have the clinical production that others such as hgsi, dna do.